These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15105158)

  • 1. Novel inhalational murine model of invasive pulmonary aspergillosis.
    Sheppard DC; Rieg G; Chiang LY; Filler SG; Edwards JE; Ibrahim AS
    Antimicrob Agents Chemother; 2004 May; 48(5):1908-11. PubMed ID: 15105158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice.
    Lewis RE; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1078-81. PubMed ID: 17194825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis.
    Kirkpatrick WR; Najvar LK; Vallor AC; Wiederhold NP; Bocanegra R; Pfeiffer J; Perkins K; Kugler AR; Sweeney TD; Patterson TF
    J Antimicrob Chemother; 2012 Apr; 67(4):970-6. PubMed ID: 22240402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Prince RA; Chi J; Kontoyiannis DP
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response.
    Becker MJ; de Marie S; Fens MH; Hop WC; Verbrugh HA; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2002 May; 49(5):813-20. PubMed ID: 12003976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis.
    Martín MT; Gavaldà J; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Jordano Q; Ruiz I; Rosal M; Almirante B; Pahissa A
    J Antimicrob Chemother; 2003 Dec; 52(6):1032-4. PubMed ID: 14613950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
    Petraitiene R; Petraitis V; Lyman CA; Groll AH; Mickiene D; Peter J; Bacher J; Roussillon K; Hemmings M; Armstrong D; Avila NA; Walsh TJ
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1188-96. PubMed ID: 15047519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings.
    Arendrup MC; O'driscoll BR; Petersen E; Denning DW
    Scand J Infect Dis; 2006; 38(10):945-9. PubMed ID: 17008247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy.
    Walsh TJ; Garrett K; Feurerstein E; Girton M; Allende M; Bacher J; Francesconi A; Schaufele R; Pizzo PA
    Antimicrob Agents Chemother; 1995 May; 39(5):1065-9. PubMed ID: 7625790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity.
    Ruijgrok EJ; Fens MH; Bakker-Woudenberg IA; van Etten EW; Vulto AG
    J Pharm Pharmacol; 2005 Oct; 57(10):1289-95. PubMed ID: 16259757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of liposomal amphotericin B for prophylaxis of acute or reactivation models of invasive pulmonary aspergillosis.
    Leleu C; Menotti J; Meneceur P; Choukri F; Sulahian A; Garin YJ; Derouin F
    Mycoses; 2013 May; 56(3):241-9. PubMed ID: 22998025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis.
    Becker MJ; de Marie S; Fens MH; Verbrugh HA; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2003 Sep; 52(3):428-34. PubMed ID: 12917249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
    Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
    J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bronchopulmonary aspergillosis: new developments].
    Germaud P; Renaudin K; Danner I; Morin O; De Lajartre AY
    Rev Mal Respir; 2001 Jun; 18(3):257-66. PubMed ID: 11468587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.
    Ullmann AJ; Krammes E; Sommer S; Buschmann I; Jahn-Muehl B; Cacciapuoti A; Schmitt HJ
    J Antimicrob Chemother; 2007 Nov; 60(5):1080-4. PubMed ID: 17855727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
    Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
    Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardization of an experimental murine model of invasive pulmonary aspergillosis.
    Sheppard DC; Graybill JR; Najvar LK; Chiang LY; Doedt T; Kirkpatrick WR; Bocanegra R; Vallor AC; Patterson TF; Filler SG
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3501-3. PubMed ID: 17005844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.
    Murphy M; Bernard EM; Ishimaru T; Armstrong D
    Antimicrob Agents Chemother; 1997 Mar; 41(3):696-8. PubMed ID: 9056016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis.
    Delmas G; Park S; Chen ZW; Tan F; Kashiwazaki R; Zarif L; Perlin DS
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2704-7. PubMed ID: 12121962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.